Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01976663 · ClinicalTrials.gov registry record · NA
A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds
A NA study, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 126
- Enrollment target
NCT01976663 is a NA study that has completed, run by Allergan. The registered enrollment target is 126 participants.
The verdict
NCT01976663, a NA study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 126 participants
- Enrollment target
Study Summary
A prospective, multicenter, within-subject controlled study of the safety and effectiveness of JUVÉDERM VOLIFT® XC versus Control for the correction of moderate to severe nasolabial folds (NLFs).
Interventions
- DEVICE Control
- DEVICE JUVEDERM VOLIFT® XC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2013-10-29 |
| Est. Completion | 2015-10-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01976663
The ClinicalTrials.gov registry entry for NCT01976663 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT01976663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01976663 about?
NCT01976663 is a clinical study titled "A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds". A prospective, multicenter, within-subject controlled study of the safety and effectiveness of JUVÉDERM VOLIFT® XC versus Control for the correction of moderate to severe nasolabial folds (NLFs).
What is the current status of trial NCT01976663?
This trial is currently completed. It is a NA study. The enrollment target is 126 participants. The study started on 2013-10-29. Estimated completion is 2015-10-26.
What interventions are being tested in trial NCT01976663?
The interventions under investigation include: Control (DEVICE), JUVEDERM VOLIFT® XC (DEVICE).
Who is sponsoring clinical trial NCT01976663?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.